Overall age-adjusted mortality rates have fallen, but the poorest parts of the world aren’t sharing in the benefits.

The most read stories this past month detailed the passing of Dimitrios Karmpaliotis and news on Evoque and COVID-19.

In EARLY TAVR, intervention improved outcomes over waiting in patients with class II or no indications for AVR consideration.

The study led to questions about whether patients would be best served by being treated at high-volume centers of excellence.